PFIZER INC
PFENYSE · SIC 2834
$25.05
↓ -0.4%Jul 17 close · end-of-day
Price
1Y↑ +8.9%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$143.6B
Enterprise Value
$198.1B
P/E
19.1
P/S
2.3
P/B
1.6
EV/EBITDA
—
PEG
—
FCF Yield
6.6%
Dividend Yield
6.9%
Revenue (TTM)
$63.3B
Net Income (TTM)
$7.5B
Free Cash Flow (TTM)
$9.5B
Gross Margin
—
Operating Margin
—
Net Margin
11.8%
ROE
8.3%
ROIC
—
Debt / Equity
0.7
Net Cash
-$54.5B
Return 1Y
+9.0%
Company profile
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health. The company also provides biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Cibinqo brands.
- CEO
- Albert Bourla
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 83,000
- Headquarters
- New York
- Website
- pfizer.com
Management & directors
- Damico Jennifer B.SVP & Controller
- Mcdermott MichaelExecutive Vice President
- Boshoff ChristoffelPresident, R&D
- Bourla AlbertChairman & CEO
- Fonseca LidiaExecutive Vice President
- Lankler Douglas MExecutive Vice President
- Sahni PayalExecutive Vice President
Roles derived from SEC Form 4 filings.
Earnings
Next earnings · estimated2026-08-04
PFE Q1 2026 Earnings
Period ends 2026-03-29
MetricActualYoY
Revenue$14.5B↑ +5.4%
Diluted EPS$0.47↓ -9.6%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $41.7B | $81.3B | $101.2B | $59.6B | $63.6B | $62.6B |
| Gross profit | — | — | — | — | — | — |
| Operating income | — | — | — | — | — | — |
| Net income | $9.2B | $22.0B | $31.4B | $2.1B | $8.0B | $7.8B |
| Diluted EPS | $1.63 | $3.85 | $5.47 | $0.37 | $1.41 | $1.36 |
| Operating cash flow | $14.4B | $32.6B | $29.3B | $8.7B | $12.7B | $11.7B |
| Free cash flow | $12.2B | $29.9B | $26.0B | $4.8B | $9.8B | $9.1B |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | 22.0% | 27.0% | 31.0% | 3.6% | 12.6% | 12.4% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $13.3B | $17.7B | $17.8B | $13.7B | $14.7B | $16.7B | $17.6B | $14.5B |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | — | — | — | — | — | — | — | — |
| Net income | $41.0M | $4.5B | $410.0M | $3.0B | $2.9B | $3.5B | -$1.6B | $2.7B |
| Diluted EPS | $0.01 | $0.78 | $0.07 | $0.52 | $0.51 | $0.62 | -$0.29 | $0.47 |
| Operating cash flow | -$1.8B | $6.7B | $6.7B | $2.3B | -$582.0M | $4.6B | $5.3B | $2.6B |
| Free cash flow | -$2.4B | $6.1B | $5.8B | $1.8B | -$1.2B | $4.0B | $4.5B | $2.2B |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | 0.3% | 25.2% | 2.3% | 21.6% | 19.9% | 21.3% | -9.4% | 18.6% |
Company news
Jul 20, 2026
- 1h agoReading Between The Lines Of JNJ Stock's Latest Calltrefis.com
- 1h agoMerck’s Keytruda Faces a Patent Cliff. These New Cancer Drugs Could Take Over.finance.yahoo.com
- 2h agoEli Lilly Stock And The Price Of Confidencetrefis.com
- 5h agoPfizer (PFE) Faces New International Patent Lawsuits Over Covid 19 Vaccinefinance.yahoo.com
- 6h ago1 Stock Under $50 to Target This Week and 2 We Questionfinance.yahoo.com
- 7h agoIs Trending Stock Pfizer Inc. (PFE) a Buy Now?finance.yahoo.com
- 12h agoCould Pfizer Ultimately Be the Biggest Winner in the $100 Billion Weight-Loss Market?fool.com
Jul 19, 2026
Jul 17, 2026
- 2d agoThe Real Question Buried Inside Merck Stock's Premium Pricetrefis.com
- 3d agoGilead Leads The Battle Vs. HIV. But Rivals Are On The Move.finance.yahoo.com
- 3d agoBoomers Swear by These High-Yield 5% and More Kings They Can Buy and Hold Forever247wallst.com
- 3d agoArbutus, Sanofi escalate mRNA patent fights; InnoCare’s TYK2 contender advancesbiopharmadive.com
- 3d ago3 High-Yield Dividend Stocks to Buy and Holdfool.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-09 | DAMICO JENNIFER B.· SVP & Controller | Sale | 2,000 | $25.70 | $51,400.00 | filing |
| 2026-03-04 | DAMICO JENNIFER B.· SVP & Controller | Tax withholding | 826 | $26.62 | $21,988.12 | filing |
| 2026-03-03 | DAMICO JENNIFER B.· SVP & Controller | Award | 16,311 | $0.00 | $0.00 | filing |
| 2026-03-03 | DAMICO JENNIFER B.· SVP & Controller | Award | 5,408 | $0.00 | $0.00 | filing |
| 2026-02-27 | DAMICO JENNIFER B.· SVP & Controller | Tax withholding | 655 | $27.65 | $18,110.75 | filing |
| 2026-02-26 | McDermott Michael· Executive Vice President | Tax withholding | 3,503 | $27.10 | $94,931.30 | filing |
| 2026-02-25 | BOURLA ALBERT· Chairman & CEO | Option exercise | 491,626 | $33.82 | $16.6M | filing |
| 2026-02-25 | BOURLA ALBERT· Chairman & CEO | Tax withholding | 467,241 | $26.92 | $12.6M | filing |
| 2026-02-25 | LANKLER DOUGLAS M· Executive Vice President | Option exercise | 122,907 | $33.82 | $4.2M | filing |
| 2026-02-25 | LANKLER DOUGLAS M· Executive Vice President | Tax withholding | 116,811 | $26.92 | $3.1M | filing |
| 2026-02-25 | Fonseca Lidia· Executive Vice President | Option exercise | 56,888 | $33.82 | $1.9M | filing |
| 2026-02-25 | SAHNI PAYAL· Executive Vice President | Option exercise | 56,888 | $33.82 | $1.9M | filing |
| 2026-02-25 | SAHNI PAYAL· Executive Vice President | Tax withholding | 54,066 | $26.92 | $1.5M | filing |
| 2026-02-25 | Fonseca Lidia· Executive Vice President | Tax withholding | 54,066 | $26.92 | $1.5M | filing |
| 2026-02-25 | McDermott Michael· Executive Vice President | Option exercise | 37,925 | $33.82 | $1.3M | filing |
| 2026-02-25 | McDermott Michael· Executive Vice President | Tax withholding | 36,044 | $26.92 | $970,304.48 | filing |
| 2026-02-25 | DAMICO JENNIFER B.· SVP & Controller | Option exercise | 17,558 | $33.82 | $593,811.56 | filing |
| 2026-02-25 | DAMICO JENNIFER B.· SVP & Controller | Tax withholding | 16,687 | $26.92 | $449,214.04 | filing |
| 2026-02-25 | BOURLA ALBERT· Chairman & CEO | Tax withholding | 8,303 | $27.09 | $224,928.27 | filing |
| 2026-02-25 | BOSHOFF CHRISTOFFEL· President, R&D | Tax withholding | 6,833 | $27.09 | $185,105.97 | filing |
| 2026-02-25 | LANKLER DOUGLAS M· Executive Vice President | Tax withholding | 2,198 | $27.09 | $59,543.82 | filing |
| 2026-02-25 | SAHNI PAYAL· Executive Vice President | Tax withholding | 1,083 | $27.09 | $29,338.47 | filing |
| 2026-02-25 | Fonseca Lidia· Executive Vice President | Tax withholding | 1,058 | $27.09 | $28,661.22 | filing |
| 2026-02-25 | McDermott Michael· Executive Vice President | Tax withholding | 679 | $27.09 | $18,394.11 | filing |
| 2026-02-25 | DAMICO JENNIFER B.· SVP & Controller | Tax withholding | 361 | $27.09 | $9,779.49 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.